Every lot of Cagri / GLP-1 is tested by an independent ISO/IEC 17025-accredited lab in the USA. 99%+ purity isn't a target here. It's the requirement.
Don't take our word for it: test any vial at an accredited lab of your choice. If HPLC purity comes back under 99%, we refund your order and pay for the test.
This is a blend. Cagri and GLP-1 are combined in a single 10 mg vial, 5 mg of each. Cagri is a long-acting amylin-analog research compound; GLP-1 is a GLP-1 receptor agonist research compound. The pairing is one of the most studied combinations in the metabolic literature, though the two are characterised separately rather than as a single formulation.
The numbers that define Cagri / GLP-1 and how it is being studied. For laboratory research use only.
2
Research Compounds
Cagri · GLP-1
10 mg
Total Per Vial
5 mg of each component
2
Pathway Arms
Amylin · incretin
4
Research Areas
Satiety signalling
Glucose handling
Energy balance
How It Works
How Cagri / GLP-1 works
The pathways Cagri / GLP-1 acts on - and what each one does. The animation traces its signal outward from the compound to every target it engages.
Signalling pathways studied in preclinical models · illustrative
Amylin Receptor Signalling
Cagri
Amylin analogs are characterised at the calcitonin and amylin receptor complexes. Satiety signalling and gastric-emptying rate are the measured endpoints.
Amylin receptor complexes
Satiety signalling
Gastric-emptying rate
Incretin Receptor Activity
GLP-1
GLP-1 receptor agonism is characterised for glucose-dependent insulin release, with gastric emptying and food-intake endpoints also measured.
GLP-1 receptor engagement
Glucose-dependent insulin release
Food-intake endpoints
Complementary Pathways
Combined
The amylin and incretin arms act through separate receptor systems and are frequently studied in parallel. No interaction data exists for this specific formulation.
Separate receptor systems
Frequently studied in parallel
Interaction not characterised
Uses & Applications
What Cagri / GLP-1 is researched for
The main areas Cagri / GLP-1 is being studied for - and the study-reported figures behind them.
Metabolic
Satiety Signalling Models
Food-intake and satiety endpoints are measured for both arms in preclinical models.
Metabolic
Glucose Handling
The incretin arm is studied for glucose-dependent insulin release.
Metabolic
Energy Balance
Energy-balance endpoints recur across the amylin and incretin literature.
Methods
Parallel-Arm Protocols
One vial supports protocols needing both arms under matched handling.
Study-reported magnitudes
Representative figures from published research. Bars fill as you scroll.
Amylin Receptor SignallingCharacterised
GLP-1 Receptor EngagementCharacterised
Satiety EndpointsMeasured
Blend Interaction DataNone
Figures are representative of published research findings and shown for reference.
Molecular Structure
The Cagri / GLP-1 molecule
An interactive 3D model rendered from the compound record - rotate and explore its structure.
Molecular model
Sequence length
blend
Physical form
Lyophilized powder blend
Documented purity
≥99% by HPLC
Compound Information
Full specification
Components
Cagri + GLP-1
Content
10 mg per vial (5 mg of each component)
Pathways
Amylin · GLP-1 incretin
Form
Lyophilized powder blend
Purity
≥99% by HPLC
Appearance
White to off-white powder
Solubility
Water-soluble
Storage
-20°C, protected from light
Classification
Research use only
FAQ
Common questions about Cagri / GLP-1
They act through separate receptor systems and are frequently studied in parallel in the metabolic literature. This vial holds both under matched handling.
No. Each compound is characterised separately and no interaction data exists for this specific blend.
Cagri 10 mg is the single-compound vial. This blend fixes the ratio at 5 mg Cagri and 5 mg GLP-1.
Each lot is analysed by reverse-phase HPLC and released at ≥99%, with a Certificate of Analysis.
Store lyophilized at -20°C for long-term stability, protected from light and moisture, and avoid repeated freeze-thaw cycles.
Research Use Only.
Not for human or veterinary use. For in-vitro laboratory research only. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.
